title: Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats.
abstract: The effect of poly-L-arginine (poly-L-Arg) on the in vivo nasal absorption of FITC-dextrans with a mean molecular weight ranging from 4.3 to 167 kDa and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats were studied. When FITC-dextrans were co-administered intranasally with 1.0 w/v% poly-L-Args of different molecular weight (MW, ca. 45.5 and 92 kDa, poly-L-Arg (50) and poly-L-Arg (100)), the bioavailability (F(infinity)) increased markedly compared with that after administration of FITC-dextran alone. However, the F(infinity) decreased exponentially with the increasing molecular weight of FITC-dextrans. There was no significant difference between the enhanced nasal absorption of FITC-dextrans achieved by the co-administration of poly-L-Arg (50) and poly-L-Arg (100). Moreover, the relationship between the F(infinity) and the molecular weight of FITC-dextrans indicated that the molecular weight of protein drugs, which exhibited efficient absorption with poly-L-Arg, was about 20 kDa, when the lower limit of bioavailability for developing a potent transnasal delivery system was assumed to be about 10%. Indeed, the nasal absorption of rhG-CSF, which has a molecular weight of 18.8 kDa, was also increased after co-administration of 1.0 w/v% poly-L-Arg (50) and the F(infinity) was about 11%. It seems likely that poly-L-Arg can be used to provide adequate nasal absorption of various protein drugs which have a molecular weight of about 20 kDa, thereby allowing the successful development of a variety of transnasal drug delivery systems.
authors.affiliation: Analytical Division, Nissan Chemical Co. Ltd., 722-1 Tsuboi, Funabashi, Chiba 274-0062, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Miyamoto
authors.forename: H
authors.initials: H
authors.lastname: Natsume
authors.forename: I
authors.initials: I
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Ohtake
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: D
authors.initials: D
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Sugibayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Morimoto
mesh_terms: D000042:Absorption / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D019540:Area Under Curve; D001120:Arginine / Q000494:pharmacology*; D003911:Dextrans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D016650:Fluorescein-5-isothiocyanate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D008970:Molecular Weight; D009296:Nasal Cavity / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins
chemical_list: D003911:Dextrans; D011994:Recombinant Proteins; C015219:fluorescein isothiocyanate dextran; D016179:Granulocyte Colony-Stimulating Factor; D001120:Arginine; D016650:Fluorescein-5-isothiocyanate